Value to the Fore: Flexible CRO Solutions Aim to Improve Pipeline Success
White Paper Apr 02, 2012
R&D outsourcing is widely used by pharmaceutical, biotechnology, agricultural and related industries. In order for this to continue, CRO's will need to make higher value contributions i collaborative drug discovery programs.
Trends indicate a return to value, as Contract Research Organizations (CROs) continue to grow their skill sets and ally with the global R&D industry to tap flexible solutions aimed at improving pipeline success. Bruce Molino, Ph.D., Senior Director of Medicinal Chemistry, and Christopher Conway, Senior Director of Business Development, AMRI, analyze the increasing demand for R&D outsourcing and examine how CROs are evolving to better meet industry needs.
Related White Papers
Asthma- and COPD-related Differential Gene Expression in Primary Human Lung FibroblastsWhite Paper
This white paper summarizes a study comparing normal versus COPD lung fibroblasts and normal versus asthma lung fibroblasts to explore differences in gene expression among the donor samples.READ MORE
Evaluating Aggregation Behaviour of Liposome-protein Complexes using NTAWhite Paper
Malvern Instruments Limited
Rapid, high-resolution characterization of liposome-insulin receptor complexes in various buffer systems by Nanoparticle Tracking AnalysisREAD MORE